On 24 October 2026 the UK Cabinet Office announced the creation of the world’s first dedicated AI Biosecurity Lab (AIBL) as part of a National AI Biosecurity Initiative. The official framing is that advances in AI create unprecedented opportunities for scientific discovery while also changing the biological risk landscape—and that the UK will harness AI’s benefits while strengthening resilience to biological threats. AIBL also sits within a broader AI security investment package announced the same day.
£100m for AIBL; £165m for the wider Initiative
The UK government is providing £100 million for AIBL. According to the same-day HM Treasury package, the National AI Biosecurity Initiative totals £165 million: £100 million for AIBL, plus £65 million to strengthen bio surveillance and develop medical countermeasures for priority pathogens.
OpenAI and Anthropic up to £200m; DeepMind and Basecamp collaborations
At launch, two frontier AI companies are committing up to about £200 million in total:
- OpenAI: £100 million in compute and model credits, plus trusted access to its most capable relevant models through the Rosalind Biodefense programme.
- Anthropic: up to £100 million in model credits, trusted model access, and dedicated technical support.
Google DeepMind scientists and biosecurity experts will partner with AIBL on research collaborations and will look to provide trusted access to frontier Gemini and specialised science models. UK AI life-sciences company Basecamp Research will provide access to its AI-biology models, capabilities, and technical expertise for priority biosecurity challenges.
Left: early-detection collaborative network nodes; right: discovery bench accelerating soft vaccine/countermeasure motifs from many candidates to a few validated results (illustration only — no text or logos).
Independent non-profit, akin to the AI Security Institute
AIBL will operate as an independent non-profit, designed—similar to the AI Security Institute—to attract leading industry and academic technical talent and to move with the autonomy, speed, and focus of a frontier AI–bio company. It will be supported by a scientific advisory committee drawing on academia, industry, and the third sector; further details will follow.
Initial focus: earlier detection and faster medical countermeasures
AIBL’s mission is to strengthen biosecurity by harnessing frontier AI—bringing together frontier AI and biological science talent to develop practical technical capabilities that improve the UK’s ability to understand, prevent, detect, and respond to biological threats. Initial delivery will focus on enhancing early detection of emerging biological threats, and on accelerating the discovery, development, and testing of vaccines, treatments, and other medical countermeasures so the UK and the world can respond faster to outbreaks and strengthen resilience against future biological risks.
Public partners: UKHSA, APHA, Dstl, and MHRA
The Initiative brings together the UK Health Security Agency (UKHSA), the Animal and Plant Health Agency (APHA), and the Defence Science and Technology Laboratory (Dstl) with AIBL and the life-sciences sector. AIBL will also work with the Medicines and Healthcare products Regulatory Agency (MHRA) to prepare for health emergencies and to inform the regulation of AI-designed medicines.
Primary sources:
- Cabinet Office, “Introducing the AI Biosecurity Lab,” 2026-10-24, https://www.gov.uk/government/news/introducing-the-ai-biosecurity-lab
- HM Treasury et al., “Chancellor unveils Britain’s ambitious plan for AI,” 2026-10-24, https://www.gov.uk/government/news/chancellor-unveils-britains-ambitious-plan-for-ai
